Prostate cancer screening comes of age
Menée à partir des données d'un essai européen incluant 162 243 participants âgés de 55 à 69 ans, cette étude évalue, après 13 ans de suivi, l'intérêt du test PSA pour réduire la mortalité par cancer de la prostate
The debate over prostate cancer screening has raged for decades. Two large randomised studies tested whether screening reduces prostate cancer mortality and, while the US trial reported no benefit, 1 the European (ERSPC) trial noted a significant reduction in mortality. 2 In The Lancet , Fritz Schroder and colleagues 3 now report 13-year mortality data from the ERSPC study. At 9 years, screening appeared to reduce prostate cancer mortality by 15% (rate ratio 0·85, 95% CI 0·70—1·03); this reduction was 2...
The Lancet , commentaire, 2013